R&D Alzheimer’s: Starting the impossible journey Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
